Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astex’s Inqovi Gets Approval in US, Canada: Otsuka
Otsuka Pharmaceutical said on July 8 that its US subsidiary Astex Pharmaceuticals’ novel cancer agent Inqovi (decitabine + cedazuridine) was approved in the US and Canada for the treatment of high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Inqovi,…
To read the full story
Related Article
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Otsuka/Astex’s Oral AML Drug Nabs European OK
September 20, 2023
- Otsuka/Astex’s AML Medicine Accepted for Review in Europe
August 23, 2022
- Astex’s Novel Cancer Drug Accepted for FDA Review: Otsuka
February 13, 2020
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Shionogi Highlights ViiV’s Long-Term HIV IP Strategy
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…